Ifosfamide with regional hyperthermia in soft-tissue sarcomas
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2003-01-01 / Oncology 2003;65 Suppl 2:76-9Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
/in Breast Cancer, International Publications /von 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer
/in Breast Cancer, International Publications /von 2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):285-94Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
/in Breast Cancer, Dendritic Cells, International Publications /von 2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine
/in HIV/AIDS, International Publications /von 2003-01-01 / Nat. Med. 2003 Jan;9(1):13-4The first 1000 dendritic cell vaccinees
/in Dendritic Cells, International Publications /von 2003-01-01 / Cancer Invest. 2003;21(6):873-86Dendritic cell vaccination and viral infection–animal models
/in Chronic Virus Hepatitis, International Publications /von 2003-01-01 / Curr. Top. Microbiol. Immunol. 2003;276:199-214
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution